GSTM1 and Neurodevelopmental delay: However, in the NDD-CKD patient group, roxadustat improved the Hb response compared with placebo and darbepoetin alfa (OR: 30.29; 95% CI: 11.55–79.42; p < 0.00001; Figure 3B and Table 3).